These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25601128)

  • 1. Rasagiline for the treatment of parkinsonism in Huntington's disease.
    Pérez-Pérez J; Martínez-Horta S; Pagonabarraga J; Carceller M; Kulisevsky J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):340-2. PubMed ID: 25601128
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.
    Poewe W; Seppi K; Fitzer-Attas CJ; Wenning GK; Gilman S; Low PA; Giladi N; Barone P; Sampaio C; Eyal E; Rascol O;
    Lancet Neurol; 2015 Feb; 14(2):145-52. PubMed ID: 25498732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
    Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.
    Reznichenko L; Kalfon L; Amit T; Youdim MB; Mandel SA
    Neurodegener Dis; 2010; 7(4):219-31. PubMed ID: 20197647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease.
    Wang SC; Lee-Chen GJ; Wang CK; Chen CM; Tang LM; Wu YR
    Mov Disord; 2004 Jul; 19(7):854-856. PubMed ID: 15254954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials for multiple system atrophy.
    Galpern WR
    Lancet Neurol; 2015 Feb; 14(2):126-7. PubMed ID: 25498733
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rasagiline in Parkinson's disease].
    Linazasoro G
    Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
    de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
    Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
    Bar-Am O; Weinreb O; Amit T; Youdim MB
    J Neurochem; 2010 Mar; 112(5):1131-7. PubMed ID: 20002521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinsonism in Huntington's disease.
    Reilmann R
    Int Rev Neurobiol; 2019; 149():299-306. PubMed ID: 31779817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case of a 29-year-old man with psychiatric illness and parkinsonism.
    Larson D
    Ann Clin Transl Neurol; 2021 Nov; 8(11):2210. PubMed ID: 34716756
    [No Abstract]   [Full Text] [Related]  

  • 13. Linking Huntington's Disease and X-linked Dystonia Parkinsonism on the Molecular Level.
    Diaw SH; Lohmann K
    Mov Disord; 2020 Oct; 35(10):1752-1753. PubMed ID: 32960466
    [No Abstract]   [Full Text] [Related]  

  • 14. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritability in a Prospective Cohort of Huntington's Disease Mutation Carriers.
    Bouwens JA; van Duijn E; van der Mast RC; Roos RA; Giltay EJ
    J Neuropsychiatry Clin Neurosci; 2015; 27(3):206-12. PubMed ID: 26067436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset dystonia and parkinsonism with abnormal globus pallidal signal in MRI: a diagnostic challenge.
    Post B; van Belzen M; Marcelis C; Meijer FJ; Willemsen MA; van de Warrenburg BP
    Mov Disord; 2013 Dec; 28(14):2035-6. PubMed ID: 24038378
    [No Abstract]   [Full Text] [Related]  

  • 19. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    Sharma JC
    Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
    [No Abstract]   [Full Text] [Related]  

  • 20. Rasagiline in neurodegeneration.
    Schapira AH
    Exp Neurol; 2008 Aug; 212(2):255-7. PubMed ID: 18571162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.